<DOC>
	<DOC>NCT00562172</DOC>
	<brief_summary>Primary objective: To compare long-term glycemic control and preservation of beta cell function when basal insulin or sulfonylurea is added on metformin in the early Type 2 Diabetes Mellitus patients Secondary objective: To assess the change of insulin resistance, microvascular complication incidence, patient satisfaction with treatment</brief_summary>
	<brief_title>Insulin Glargine (Lantus) vs Sulfonylurea (SU) for BETA Cell Function (BETA Study)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>List of Inclusion and Type 2 Diabetes Mellitus patients on metformin monotherapy 7% ≤ HbA1c ≤ 12% 20 kg/m² ≤BMI ≤ 35 kg/m² Diabetes duration: at least 6 months Type 1 Diabetes Mellitus patients Clinical evidence of active liver disease, or serum Alanine AminoTransferase 3 times the upper limit of the normal range Serum creatinine: 1.5 mg/dl for males, 1.4 mg/dl for females Acute and chronic metabolic acidosis, including diabetic ketoacidosis History of alcohol or other substance abuse Pregnancy or not using contraceptive in childbearing aged women Known hypersensitivity to Lantus, SU or metformin Any disease or condition that in the opinion of the investigator may interfere with completion of the study The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>